These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 7564157

  • 1. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W.
    Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
    [Abstract] [Full Text] [Related]

  • 2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 3. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W, Cantin EM, Finke J, Dölken G.
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 6. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W, Daskalakis M, Finke J, Dölken G.
    FEBS Lett; 1994 Jan 31; 338(2):175-8. PubMed ID: 8307177
    [Abstract] [Full Text] [Related]

  • 7. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H, Mills K, Gibson I.
    Leukemia; 1996 Jun 31; 10(6):1054-64. PubMed ID: 8667643
    [Abstract] [Full Text] [Related]

  • 8. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH, Wu SC, Chen WS, Yen CC, Yang MH, Tsai YC, Chen PM.
    Biochem Biophys Res Commun; 2004 Jun 04; 318(3):764-72. PubMed ID: 15144904
    [Abstract] [Full Text] [Related]

  • 9. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK, Nabissa PM, Reddy EP.
    Oncogene; 1993 Nov 04; 8(11):3183-8. PubMed ID: 8414522
    [Abstract] [Full Text] [Related]

  • 10. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M, Kuwabara T, Taira K.
    Nucleic Acids Symp Ser; 1997 Nov 04; (37):213-4. PubMed ID: 9586075
    [Abstract] [Full Text] [Related]

  • 11. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y, Chen YZ, Huang HF, Chen P, Lu LH.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep 04; 35(9):859-63. PubMed ID: 12958661
    [Abstract] [Full Text] [Related]

  • 12. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S, Chai YB, Liu F, Zhang XY, Jia W, Xie X, Yu WQ, Shang ZC, Jin BQ, Sun BZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):198-202. PubMed ID: 15854468
    [Abstract] [Full Text] [Related]

  • 13. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R, Haas R, Sczakiel G.
    J Mol Biol; 1996 Jun 21; 259(4):632-44. PubMed ID: 8683570
    [Abstract] [Full Text] [Related]

  • 14. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL, Lewalle P, Martiat P.
    Stem Cells; 1993 Oct 21; 11 Suppl 3():89-95. PubMed ID: 8298481
    [Abstract] [Full Text] [Related]

  • 15. [The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells].
    Feng Q, Sun B, Sun K, Shang Z, Wang S, Wang W, Zhao Y, Yan Z, Han W, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2002 Sep 21; 24(5):435-9. PubMed ID: 12485492
    [Abstract] [Full Text] [Related]

  • 16. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
    Feng Q, Sun B, Zhao Y.
    Zhonghua Yi Xue Za Zhi; 2000 Feb 21; 80(2):127-30. PubMed ID: 11798747
    [Abstract] [Full Text] [Related]

  • 17. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA, Milliken S, Biggs JC, Kearney P.
    Antisense Nucleic Acid Drug Dev; 1998 Feb 21; 8(1):15-23. PubMed ID: 9512092
    [Abstract] [Full Text] [Related]

  • 18. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Feb 21; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

  • 19. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L, Fajkus J, Polácková K, Fulnecek J, Dvoráková D, Krahulcová E.
    Blood Cells Mol Dis; 2000 Jun 21; 26(3):193-204. PubMed ID: 10950939
    [Abstract] [Full Text] [Related]

  • 20. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS, Wu Y, McMahon R, Yu L, Rossi JJ, Forman SJ.
    Biol Blood Marrow Transplant; 1997 Oct 21; 3(4):179-86. PubMed ID: 9360779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.